United States Drug Manufacturers - General news

02:07 23 Jul 2026

Ad-hoc-news.de Earnings Main company 🇺🇸 United States

Grifols stock trades steady as debt reduction and margin recovery shape investor focus

Grifols stock is holding steady as the Spanish plasma specialist focuses on debt reduction and margin recovery. Recent quarterly figures show improved adjusted earnings, higher operating margins, and a reduction in net debt, driven by better utilization of plasma centers and cost discipline. The …

GRFS main company

Sharemaestro market context Price below Trend Line 52 weeks -23.4%

22:45 22 Jul 2026

finance.yahoo.com Earnings Main company 🇺🇸 United States

Here's Why Novo Nordisk (NVO) Fell More Than Broader Market

In the latest close session, Novo Nordisk (NVO) was down 2.41% at $48.19. This move lagged the S&P 500's daily loss of 0.14%. Elsewhere, the Dow saw a downswing of 0.01%, while the tech-heavy Nasdaq depreciated by 0.57%. The drugmaker's shares have seen an …

NVO main company

Sharemaestro market context Trend signal started 52 weeks -16.7%

22:40 22 Jul 2026

RAPS Market update Main company 🇺🇸 United States

FDA issues untitled letters to Sanofi and Viatris for false advertising

The FDA's Office of Prescription Drug Promotion has sent untitled letters to Sanofi and Viatris for making misleading claims in their product promotions. Sanofi was cited for an email promoting Beyfortus, which incorrectly suggested it prevents general RSV, while Viatris was reprimanded for a …

SNY main company

Sharemaestro market context Price below Trend Line 52 weeks -10.1% · Next-week setup positive 56.1%

22:38 22 Jul 2026

NBC New York Regulatory and legal Main company 🇺🇸 United States

Novo Nordisk sues rival Eli Lilly over ‘misleading' weight-loss drug advertising

Novo Nordisk has filed a lawsuit against Eli Lilly, accusing the rival pharmaceutical company of false advertising regarding its weight-loss drugs Mounjaro and Zepbound. Novo Nordisk claims Eli Lilly's advertising campaigns rely on outdated studies, comparing their highest doses with lower doses of Novo …

LLY main company

Sharemaestro market context Trend signal active 52 weeks +66.6% · Next-week setup positive 58.3%

22:21 22 Jul 2026

Investing.com Market update Main company 🇺🇸 United States

FDA accepts Pfizer filing for Talzenna-Xtandi prostate cancer use

Pfizer Inc. announced that the FDA has accepted its supplemental New Drug Application for a Priority Review of TALZENNA in combination with XTANDI for men with homologous recombination repair gene-altered metastatic castration-sensitive prostate cancer. The FDA's Prescription Drug User Fee Act action date is …

PFE main company

Sharemaestro market context Price above Trend Line 52 weeks +8.9%

22:13 22 Jul 2026

Sanofi Market update Main company 🇺🇸 United States

How AI is Reshaping the Patient Care Journey

Sanofi is leveraging Digital and AI technologies to transform the patient care journey, addressing fragmentation from diagnosis to long-term treatment. Their approach spans pre-prescription (identification and diagnosis) and post-prescription (onboarding and support) phases. By integrating AI-driven tools like AccelRare, FabryFind, iCare+, and Companion App, …

SNY main company

Sharemaestro market context Price below Trend Line 52 weeks -10.1% · Next-week setup positive 56.1%

22:12 22 Jul 2026

TradingView Deals and strategy Main company 🇺🇸 United States

Scilex Sells Vivasor Preferred Shares Back for $12.0 Million, Paid in Tranches Through 2027

Scilex (SCLX) has entered into a stock repurchase agreement to sell its previously acquired Vivasor preferred shares back to Vivasor for approximately $12.0 million. The payment will be made in five tranches from July 18, 2026, through June 30, 2027. This transaction aims to …

SCLX main company

Sharemaestro market context Trend signal active 52 weeks -42.5% · Next-week setup negative 43.9%

22:09 22 Jul 2026

Quartr Deals and strategy Main company 🇺🇸 United States

GSK (GSK) Q4 2024 earnings summary

GSK announced strong Q4 2024 results with 8% sales growth to over GBP 31.4 billion, driven by specialty medicines and vaccines. Core operating profit increased by 13%, and core EPS rose by 12% to 159.3p, leading to a dividend increase and a new GBP …

GSK main company

Sharemaestro market context Price below Trend Line 52 weeks +26.3% · Next-week setup positive 55.6%

22:08 22 Jul 2026

finance.yahoo.com Regulatory and legal Main company 🇺🇸 United States

Pfizer (PFE) Faces Expanded Vaccine Lawsuits On A Fair Value Narrative That Still Sees Upside

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Pfizer (PFE) is back in focus after Arbutus Biopharma and Genevant Sciences expanded their patent litigation over mRNA lipid nanoparticle technology, adding new …

PFE main company

Sharemaestro market context Price above Trend Line 52 weeks +8.9%

21:58 22 Jul 2026

plansponsor Market update Main company 🇺🇸 United States

DOL Anchors Wave of Briefs Backing Bristol-Myers in PRT Appeal

The U.S. Department of Labor has filed an amicus brief supporting Bristol-Myers Squibb in a pension risk transfer (PRT) appeal, joining business groups, insurers, and states. They argue that retirees lack Article III standing as they still receive full benefits and that allowing such …

BMY main company

Sharemaestro market context Trend signal active 52 weeks +38.1%

21:49 22 Jul 2026

Reuters Market update Main company 🇺🇸 United States

Pfizer's prostate cancer drug combination gets US FDA priority review

Pfizer announced that the U.S. Food and Drug Administration has granted priority review for an expanded approval of its prostate cancer drug combination, Talzenna and Xtandi. This combination targets men with metastatic castration-sensitive prostate cancer who have HRR mutations. The FDA is expected to …

PFE main company

Sharemaestro market context Price above Trend Line 52 weeks +8.9%

21:43 22 Jul 2026

U.S. News & World Report Regulatory and legal Main company 🇺🇸 United States

US Judge Casts Doubt on 69,000 Cases Alleging J&J Talc Caused Cancer

A federal judge has questioned the validity of approximately 69,000 lawsuits claiming Johnson & Johnson's talc products caused ovarian cancer, demanding plaintiffs provide more specific evidence. U.S. Magistrate Judge Rukhsanah Singh expressed doubt after expert testimony indicated an inability to definitively link talcum powder …

JNJ main company

Sharemaestro market context Trend signal active 52 weeks +48.8%

21:31 22 Jul 2026

Stock Titan Market update Main company 🇺🇸 United States

Pfizer trial: TALZENNA combo cut progression-or-death risk 52%

Pfizer announced that the FDA has accepted for Priority Review a supplemental New Drug Application (sNDA) for TALZENNA in combination with XTANDI for men with HRR gene-altered metastatic castration-sensitive prostate cancer (mCSPC). The sNDA is supported by Phase 3 TALAPRO-3 trial data showing the …

PFE main company

Sharemaestro market context Price above Trend Line 52 weeks +8.9%

21:30 22 Jul 2026

finance.yahoo.com Earnings Main company 🇺🇸 United States

FDA Grants Priority Review for Pfizer’s TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer

Supplemental application aims to expand use to men with HRR gene-mutated metastatic castration-sensitive prostate cancer Filing supported by Phase 3 TALAPRO-3 data demonstrating greater than 50% improvement in radiographic progression-free survival, with consistent benefit across BRCA and non-BRCA HRR gene alterations NEW YORK, July …

PFE main company

Sharemaestro market context Price above Trend Line 52 weeks +8.9%

21:10 22 Jul 2026

Stocktwits Earnings Main company 🇺🇸 United States

AMRN: Amarin Corp - ADR Latest Stock Price, Analysis, News and Trading Ideas

This page provides current stock information for Amarin Corp (AMRN), including its latest stock price, market capitalization, volume, and upcoming earnings date. It also lists recent financial news related to other pharmaceutical companies and trending stock discussions. The stock is currently trading at $13.69, …

AMRN main company

Sharemaestro market context Price below Trend Line 52 weeks -12.0%

21:07 22 Jul 2026

WSJ Market update Main company 🇺🇸 United States

Biogen CEO: Lessons from Biopharma on Leading Reinvention

Biogen CEO Chris Viehbacher discusses his framework for leading reinvention in the biopharma industry, emphasizing the structural necessity of transformation due to patent expirations. He highlights the importance of assessing pipeline, capabilities, and people to build a credible vision for the future, rather than …

BIIB main company

Sharemaestro market context Trend signal active 52 weeks +50.6% · Next-week setup positive 55.3%

21:07 22 Jul 2026

MarketWatch Market update Main company 🇺🇸 United States

AbbVie Inc. stock underperforms Wednesday when compared to competitors

AbbVie Inc. (ABBV) shares fell 1.09% on Wednesday, closing at $253.30, and underperformed the broader market, with both the S&P 500 and Dow Jones Industrial Average also seeing slight declines. The stock is currently 3.19% below its 52-week high reached earlier in July.

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +21.3% · Next-week setup positive 57.6%

21:06 22 Jul 2026

TradingView Market update Main company 🇺🇸 United States

Total equity of AbbVie, Inc. – BCS:ABBV0

This article provides the total equity information for AbbVie, Inc. (BCS:ABBV0) from the Santiago Stock Exchange, accessed via TradingView. It indicates that the market was closed at the time of viewing and no trades were recorded. The content is primarily a data page with …

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +21.3% · Next-week setup positive 57.6%

20:35 22 Jul 2026

Simply Wall Street Regulatory and legal Main company 🇺🇸 United States

Pfizer (PFE) Faces New Patent Lawsuits Over Covid 19 Vaccine Technology

Pfizer is facing new international patent lawsuits from Arbutus Biopharma and Genevant Sciences concerning its mRNA lipid nanoparticle COVID-19 vaccine technology. These lawsuits, extending from existing U.S. disputes, seek injunctions and monetary damages in Canada and the EU, adding legal uncertainty to Pfizer's mRNA …

PFE main company

Sharemaestro market context Price above Trend Line 52 weeks +8.9%

19:40 22 Jul 2026

Fierce Pharma Market update Main company 🇺🇸 United States

FDA calls out Sanofi emails for giving 'misleading impression' of Beyfortus use in RSV

The FDA has issued an untitled letter to Sanofi regarding its promotional emails for the RSV antibody Beyfortus. The agency claims Sanofi's emails create a "misleading impression" by presenting Beyfortus as a general RSV preventative, rather than specifically for lower respiratory tract disease as …

SNY main company

Sharemaestro market context Price below Trend Line 52 weeks -10.1% · Next-week setup positive 56.1%

19:07 22 Jul 2026

Zacks Earnings Main company 🇺🇸 United States

Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for

Biogen Inc. (BIIB) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare …

BIIB main company

Sharemaestro market context Trend signal active 52 weeks +50.6% · Next-week setup positive 55.3%

18:57 22 Jul 2026

Bloomberg Law News Regulatory and legal Main company 🇺🇸 United States

AbbVie Sues Galderma Over Patented Dermal Filler Syringe Designs

AbbVie Inc. and its Allergan Inc. unit have filed a patent infringement lawsuit against Galderma Group AG and Galderma SA. The lawsuit alleges that Galderma created dermal filler syringes for its Restylane product with a design similar to AbbVie's Juvéderm syringes, infringing on several …

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +21.3% · Next-week setup positive 57.6%

18:06 22 Jul 2026

TradingView Earnings Main company 🇺🇸 United States

Will AbbVie's Oncology Franchise Remain Under Pressure in Q2?

AbbVie's oncology franchise is facing continued pressure, primarily due to declining Imbruvica sales, despite growth from newer therapies. The Zacks Consensus Estimate for Q2 oncology revenues suggests a slight decline from the previous year. The company's stock has outperformed the industry year-to-date, and it …

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +21.3% · Next-week setup positive 57.6%

17:56 22 Jul 2026

MarketWatch Market update Main company 🇺🇸 United States

Biogen Inc. stock underperforms Wednesday when compared to competitors

Shares of Biogen Inc. (BIIB) fell 2.67% on Wednesday to $197.74, underperforming the broader stock market, which also saw declines for the S&P 500 Index and Dow Jones Industrial Average. The stock closed 10.00% below its 52-week high reached on June 29th.

BIIB main company

Sharemaestro market context Trend signal active 52 weeks +50.6% · Next-week setup positive 55.3%

17:43 22 Jul 2026

Stock Titan Regulatory and legal Main company 🇺🇸 United States

GSK (NYSE: GSK) gains early FDA approval for ROS1 lung cancer therapy

GSK has received early FDA approval for Jideytro (zidesamtinib), a therapy for ROS1-positive non-small cell lung cancer in adult patients who have previously used a ROS1 kinase inhibitor. This approval, based on the ARROS-1 trial showing a 44% objective response rate, comes ahead of …

GSK main company

Sharemaestro market context Price below Trend Line 52 weeks +26.3% · Next-week setup positive 55.6%

17:29 22 Jul 2026

MassLive Regulatory and legal Main company 🇺🇸 United States

|‘Deliberately false’ and ‘outdated’: Eli Lilly slammed with lawsuit over weight-loss drug ads

Novo Nordisk has filed a lawsuit against Eli Lilly, accusing the company of using "deliberately false" and "outdated" advertising comparisons for its weight-loss and diabetes drugs, Zepbound and Mounjaro. Novo Nordisk claims that Lilly's ad campaigns compare its products to lower, outdated doses of …

LLY main company

Sharemaestro market context Trend signal active 52 weeks +66.6% · Next-week setup positive 58.3%

16:38 22 Jul 2026

Stocktwits Earnings Main company 🇺🇸 United States

LLY: Lilly(Eli) & Co Latest Stock Price, Analysis, News and Trading Ideas

This page provides the latest stock information for Eli Lilly & Co (LLY), including its current price, market capitalization, volume, and key financial metrics. It also features recent news, such as a lawsuit from Novo Nordisk regarding advertising, and announcements of upcoming earnings. Additionally, …

LLY main company

Sharemaestro market context Trend signal active 52 weeks +66.6% · Next-week setup positive 58.3%

16:16 22 Jul 2026

The Hollywood Reporter Market update Main company 🇺🇸 United States

How Gilead Is Working With Cultural Influencers to Bring Attention to HIV Stigma and Elevate HIV Prevention

Gilead Sciences is engaging cultural influencers and artists to combat HIV stigma and increase awareness, as scientific advancements in treating and preventing HIV are not being matched by public understanding. Despite progress turning HIV into a manageable chronic condition, knowledge about the virus is …

GILD main company

Sharemaestro market context Price above Trend Line 52 weeks +23.7%

16:09 22 Jul 2026

Proactive financial news Market update Main company 🇺🇸 United States

Jefferies says September lung data can offset AstraZeneca trial failure

Jefferies believes that forthcoming detailed data on AstraZeneca's experimental lung drug, tozorakimab, could mitigate the impact of a recent heart trial failure. The bank reiterated its "buy" rating and a 17,500p price target, citing the drug's potential to treat chronic obstructive pulmonary disease regardless …

AZN main company

Sharemaestro market context Price below Trend Line 52 weeks -1.4%

15:42 22 Jul 2026

finance.yahoo.com Regulatory and legal Main company 🇺🇸 United States

NVO Challenges LLY Ads in GLP-1 Battle: Why the Lawsuit Matters Now

Novo Nordisk NVO has filed a lawsuit against Eli Lilly LLY, accusing its rival of misleading high-profile U.S. advertising campaigns to promote its blockbuster injectable GLP-1 medicines, Zepbound and Mounjaro, over NVO's injectable semaglutide medicines, Wegovy and Ozempic for obesity and type II diabetes …

NVO main company

Sharemaestro market context Trend signal started 52 weeks -16.7%

15:38 22 Jul 2026

The Guardian Earnings Main company 🇺🇸 United States

Ozempic maker Novo Nordisk sues US rival over ‘materially misleading’ ads

Novo Nordisk, the maker of Ozempic, is suing its US rival Eli Lilly, alleging that Eli Lilly's advertisements for its weight-loss treatments, Zepbound and Mounjaro, are "false and materially misleading." Novo Nordisk claims that Eli Lilly used outdated trial data to make its drugs …

LLY main company

Sharemaestro market context Trend signal active 52 weeks +66.6% · Next-week setup positive 58.3%

15:34 22 Jul 2026

TipRanks Regulatory and legal Main company 🇺🇸 United States

Johnson & Johnson Stock (JNJ) Rises as Robotic Surgery Device Is Approved

Johnson & Johnson's stock rose following FDA approval of its Ottava robotic surgical system. This approval allows the company to enter the soft-tissue robotic surgery market, competing with Intuitive Surgical and Medtronic. The Ottava system, designed to save space, is now set for a …

JNJ main company

Sharemaestro market context Trend signal active 52 weeks +48.8%

15:31 22 Jul 2026

finance.yahoo.com Regulatory and legal Main company 🇺🇸 United States

CAR T-Cell Therapy for Non-Hodgkin Lymphoma Market Set for Robust Growth at a CAGR of ~7% Through 2036, Driven by Expanding Indications and Clinical Adoption | DelveInsight

The CAR T-cell therapy for NHL market is witnessing rapid expansion, driven by the transition from conventional chemo-immunotherapy to advanced cell-based treatment modalities. Strong efficacy in R/R disease, growing adoption in 2L and beyond, and the launch of emerging therapies such as Zamtocabtagene autoleucel …

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

15:11 22 Jul 2026

富途牛牛 Earnings Main company 🇺🇸 United States

BofA Securities Maintains Novartis AG(NVS.US) With Buy Rating

BofA Securities has reiterated its Buy rating on Novartis AG (NVS.US). This endorsement suggests the firm's continued confidence in the pharmaceutical company's financial prospects and market performance. Investors will likely view this as a positive signal for Novartis.

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

15:07 22 Jul 2026

Market source Deals and strategy Main company 🇺🇸 United States

The Zacks Analyst Blog Highlights Eli Lilly, Costco Wholesale, Morgan Stanley and Kewaunee Scientific

This Zacks Analyst Blog highlights detailed research reports on four key stocks: Eli Lilly (LLY), Costco Wholesale (COST), Morgan Stanley (MS), and Kewaunee Scientific (KEQU). The article provides insights into each company's recent performance, growth drivers, challenges, and future outlook, based on analysis from …

LLY main company

Sharemaestro market context Trend signal active 52 weeks +66.6% · Next-week setup positive 58.3%

15:05 22 Jul 2026

GuruFocus Regulatory and legal Main company 🇺🇸 United States

Amgen (AMGN) Settles Lawsuit for $74 Million Over Tax Disclosure Delay

Amgen has agreed to a $74 million settlement over allegations it delayed disclosing a potential $10.7 billion tax liability to the U.S. IRS, stemming from alleged improper profit allocation to a Puerto Rico subsidiary. Despite this setback, Amgen holds a strong GF Score™ of …

AMGN main company

Sharemaestro market context Trend signal active 52 weeks +44.4%